AWM
NYMX

AE Wealth Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

AE Wealth Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$34K – 633
2018
Q2 		$34K Hold
10,000
– – ﹤0.01% 447
2018
Q1 		$42K Buy
+10,000
New +$34.7K ﹤0.01% 435

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

AE Wealth Management's NYMX Position: Q3 2018 in Review

AE Wealth Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2018, closing a stake of 10,000 shares — an estimated $34K sold.

AE Wealth Management first reported a position in NYMX in Q1 2018 and held it in 2 quarters. The position peaked at $42K in Q1 2018. 46 funds tracked by Wall St. Rank hold NYMX as of Q3 2018.

  • AE Wealth Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2018 after selling out during the quarter.
  • AE Wealth Management sold 10,000 Nymox Pharmaceutical Corp shares in Q3 2018, an estimated $34K.
  • AE Wealth Management first reported a position in Nymox Pharmaceutical Corp in Q1 2018 and held it in 2 quarters.
  • AE Wealth Management's Nymox Pharmaceutical Corp position peaked at $42K in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2018.

Based on AE Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.